Moreover, the administration of IFN-based therapies was often impeded by the prevalence of hematologic complications, including leukopenia, thrombocytopenia, and anemia, which were attributed to the myelosuppressive effects of IFN [22]. The gene discussed is IFNA1; the disease is anemia.